CY1113183T1 - Χρηση νατριουριτικου πεπτιδιου για θεραπεια καρδιακης ανεπαρκειας - Google Patents

Χρηση νατριουριτικου πεπτιδιου για θεραπεια καρδιακης ανεπαρκειας

Info

Publication number
CY1113183T1
CY1113183T1 CY20121100652T CY121100652T CY1113183T1 CY 1113183 T1 CY1113183 T1 CY 1113183T1 CY 20121100652 T CY20121100652 T CY 20121100652T CY 121100652 T CY121100652 T CY 121100652T CY 1113183 T1 CY1113183 T1 CY 1113183T1
Authority
CY
Cyprus
Prior art keywords
hours
deficiency treatment
heart deficiency
natural purpose
treatment
Prior art date
Application number
CY20121100652T
Other languages
English (en)
Inventor
Veselin Mitrovic
Hartmut Luss
Wolf-Georg Forssmann
Markus Meyer
Klaus Dohler
Original Assignee
Cardiopep Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardiopep Pharma Gmbh filed Critical Cardiopep Pharma Gmbh
Publication of CY1113183T1 publication Critical patent/CY1113183T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Η παρούσα αφορά στην χρήση ενός νατριουρητικού πεπτιδίου, όπως ουροδιλατίνης, για την θεραπεία ενός ασθενούς που υποφέρει από καρδιακή ανεπάρκεια, όπως οξεία καρδιακή ανεπάρκεια μετά νεφρωτικού συνδρόμου. Κατά προτίμηση, μια σύνθεση περιλαμβάνουσα αποτελεσματική ποσότητα ουροδιλατίνης χορηγείται ενδοφλεβίως στον ασθενή συνεχώς σε μια χρονική περίοδο τουλάχιστον 24 ωρών και μέχρι 120 ωρών, κατά προτίμηση 48 ωρών.
CY20121100652T 2005-04-07 2012-07-23 Χρηση νατριουριτικου πεπτιδιου για θεραπεια καρδιακης ανεπαρκειας CY1113183T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US66978605P 2005-04-07 2005-04-07
US66975105P 2005-04-08 2005-04-08
US73258505P 2005-11-01 2005-11-01
EP06749753A EP1865976B1 (en) 2005-04-07 2006-04-07 Use of natriuretic peptide for treating heart failure

Publications (1)

Publication Number Publication Date
CY1113183T1 true CY1113183T1 (el) 2016-04-13

Family

ID=37087353

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100652T CY1113183T1 (el) 2005-04-07 2012-07-23 Χρηση νατριουριτικου πεπτιδιου για θεραπεια καρδιακης ανεπαρκειας

Country Status (10)

Country Link
US (5) US7732406B2 (el)
EP (2) EP1865976B1 (el)
CY (1) CY1113183T1 (el)
DK (2) DK2510942T3 (el)
ES (2) ES2392892T3 (el)
HU (1) HUE026231T2 (el)
PL (2) PL2510942T3 (el)
PT (2) PT1865976E (el)
SI (1) SI2510942T1 (el)
WO (1) WO2006110743A1 (el)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1759001B1 (en) 2004-04-21 2011-04-13 Enobia Pharma Inc. Bone delivery conjugates and method of using same to target proteins to bone
EP1865976B1 (en) 2005-04-07 2012-05-23 Cardiopep Pharma GmbH Use of natriuretic peptide for treating heart failure
US7606617B2 (en) * 2006-01-31 2009-10-20 Cardiac Pacemakers, Inc. Urinalysis for the early detection of and recovery from worsening heart failure
US20080181903A1 (en) * 2006-12-21 2008-07-31 Pdl Biopharma, Inc. Conjugate of natriuretic peptide and antibody constant region
CN101541957B (zh) 2007-07-20 2013-08-14 梅约医学教育与研究基金会 利尿钠多肽
EP2185183B1 (en) * 2007-09-11 2016-03-16 Cardiopep Pharma GmbH Use of natriuretic peptides for treating angioedema syndromes
EP2078530A1 (en) * 2008-01-08 2009-07-15 Pharis Biotec GmbH Use of natriuretic peptides for treating angioedema syndromes
WO2010033240A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
US20130197188A1 (en) * 2010-03-15 2013-08-01 Wolf-Georg Forssmann Use of urodilatin for preparing a medicament for the treatment of cardiovascular, renal, pulmonary and neuronal syndromes while avoiding a rebound
CA2823066A1 (en) 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
WO2012115772A2 (en) * 2011-02-25 2012-08-30 Medtronic, Inc. Therapy for kidney disease and/or heart failure
US20150038418A1 (en) * 2011-07-27 2015-02-05 Medtronic, Inc. Natriuretic peptide compositions and methods of preparation
WO2013032784A1 (en) 2011-08-30 2013-03-07 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
WO2013033675A1 (en) 2011-09-02 2013-03-07 Medtronic, Inc. Chimeric natriuretic peptide compositions and methods of preparation
US9611305B2 (en) 2012-01-06 2017-04-04 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
CA2898571A1 (en) * 2013-01-25 2014-07-31 Cardiorentis Ltd. Methods of treating cardiovascular indications
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
MX2017007392A (es) 2014-12-05 2019-01-24 Alexion Pharma Inc Tratamiento de convulsiones con fosfatasa alcalina recombinante.
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
AU2016308624B2 (en) 2015-08-17 2022-06-23 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
JP6868617B2 (ja) 2015-09-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定
EP3368062A4 (en) 2015-10-30 2019-07-03 Alexion Pharmaceuticals, Inc. METHODS OF TREATING CRANIOSYNOSTOSIS IN A PATIENT
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
EP3436052A4 (en) 2016-04-01 2019-10-09 Alexion Pharmaceuticals, Inc. TREATMENT OF MUSCLE WEAKNESS USING ALKALINE PHOSPHATASES
EP3436020A4 (en) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
US11116821B2 (en) 2016-08-18 2021-09-14 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
EP3600383A4 (en) 2017-03-31 2020-10-28 Alexion Pharmaceuticals, Inc. METHODS FOR TREATMENT OF HYPOPHOSPHATASIA (HPP) IN ADULTS AND ADOLESCENTS
CN109838289B (zh) * 2017-11-27 2022-03-15 罗伯特·博世有限公司 尿素水溶液喷射系统的回抽过程监测系统和方法
EP3773684A1 (en) 2018-03-30 2021-02-17 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins
WO2021183928A1 (en) * 2020-03-13 2021-09-16 Mayo Foundation For Medical Education And Research Assessing and treating acute decompensated heart failure
WO2022029499A1 (en) * 2020-08-06 2022-02-10 Ads Aiphia Development Services Ag Methods of treating refractory ascites
EP4291224A1 (en) 2021-02-12 2023-12-20 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346953A1 (de) 1983-12-24 1985-08-14 Organogen Medizinisch-Molekularbiologische Forschungsgesellschaft mbH, 6900 Heidelberg Cardiodilatin, ein neues peptidhormon und verfahren zu seiner herstellung
US5449751A (en) 1987-03-02 1995-09-12 Pharma Bissendorf Peptide Gmbh Cardiodilatin fragment, process for preparing same and use thereof
JP2819467B2 (ja) 1987-03-02 1998-10-30 ファーマ・ビッセンドルフ・ペプタイド・ゲーエムベーハー 新規なカルジオジラチン断片およびその製造方法
US5461142A (en) * 1987-11-07 1995-10-24 Pharma Bissendorf Peptide Gmbh Phosphorylated derivatives of cardiodilatin/ANF peptides
US5166191A (en) 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
DE4216133A1 (de) * 1992-05-15 1993-11-18 Bissendorf Peptide Gmbh Anwendung von Urodilatin bei Lungen- und Bronchialerkrankungen
US5514670A (en) * 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
AU2671795A (en) 1994-06-02 1996-01-04 Boehringer Mannheim Gmbh Process and intermediate products for preparing cardiodilatin fragments, and highly purified cardiodilatin fragments
US5741776A (en) 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
AU6820898A (en) 1997-04-04 1998-10-30 Novo Nordisk A/S Natriuretic peptide derivatives
DE19951471A1 (de) 1999-10-26 2001-05-03 Forssmann Wolf Georg Verwendung von Urodilatin zur Behandlung chronischer Niereninsuffizienz mit Nierenrestfunktionen
US6831084B1 (en) 1999-11-12 2004-12-14 Wyeth Branched adamantyl and noradamantyl aryl- and aralkylpiperazines with serotonin 5-HT1A activity
US6407211B1 (en) 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
CA2425712C (en) 2000-10-04 2017-06-06 Molecular Medicine Research Institute Methods of modulating apoptosis by administration of relaxin agonists or antagonists
KR101271635B1 (ko) 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
US20040063630A1 (en) 2002-03-18 2004-04-01 Scios, Inc. Treatment of congestive heart failure with natriuretic peptide and a diuretic
US20050113286A1 (en) 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
AU2003297583B2 (en) * 2002-11-26 2010-01-14 Biocon, Ltd Modified naturetic compounds, conjugates, and uses thereof
US20060008415A1 (en) 2004-06-25 2006-01-12 Protein Design Labs, Inc. Stable liquid and lyophilized formulation of proteins
WO2006041855A2 (en) 2004-10-04 2006-04-20 Nitromed, Inc. Compositions and methods using apocynin compounds and nitric oxide donors
CA2597460A1 (en) 2005-02-24 2006-08-31 Nitromed, Inc. Nitric oxide enhancing diuretic compounds, compositions and methods of use
EP1865976B1 (en) 2005-04-07 2012-05-23 Cardiopep Pharma GmbH Use of natriuretic peptide for treating heart failure
US20100168011A1 (en) 2006-12-12 2010-07-01 Amylin Pharmaceuticals, Inc. Pharmaceutical Formulations and Methods for Making the Same
US20080181903A1 (en) 2006-12-21 2008-07-31 Pdl Biopharma, Inc. Conjugate of natriuretic peptide and antibody constant region
EP2185183B1 (en) 2007-09-11 2016-03-16 Cardiopep Pharma GmbH Use of natriuretic peptides for treating angioedema syndromes
EP2190450A2 (en) 2007-09-11 2010-06-02 Mondobiotech Laboratories AG Use of melanin concentrating hormone and met-enkephalin as therapeutic agents
US20090163421A1 (en) 2007-12-19 2009-06-25 Ekr Therapeutics, Inc. Room Temperature Stable, Lyophilized Natriuretic Peptide Formulations
WO2009086126A2 (en) 2007-12-21 2009-07-09 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
US8642550B2 (en) 2008-10-24 2014-02-04 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides without hypotensive inducing capability
WO2010065293A1 (en) 2008-12-03 2010-06-10 Boehringer Ingelheim Pharmaceuticals Inc. Antibodies for guanylyl cyclase receptors
CA2754408A1 (en) 2009-03-30 2010-10-14 Boehringer Ingelheim International Gmbh Fusion proteins comprising canine fc portions
US20110065676A1 (en) 2009-06-24 2011-03-17 Schering Corporation Combination therapies comprising par1 antagonists with nar agonists
US20110014180A1 (en) 2009-07-16 2011-01-20 Masafumi Koide Preparations for tissue restoration containing atrial diuretic hormone and family molecules as active ingredients; method of restoring tissue using the preparation; agents for growing, restoring, promoting growth of hair and agents for promoting restoration of skin tissue and cardiac muscle tissue containing atrial diuretic hormone family molecules as active ingredients; method of growing, restoring, promoting growth of hair by using the agents; and method of promoting restoration of skin tissue and cardiac muscle tissue
WO2011038066A2 (en) 2009-09-25 2011-03-31 Alcon Research, Ltd. Novel npr-b agonists
CN102548574B (zh) 2009-09-25 2016-03-23 夏尔孤儿治疗有限公司 Npr-b激动剂
US20130197188A1 (en) 2010-03-15 2013-08-01 Wolf-Georg Forssmann Use of urodilatin for preparing a medicament for the treatment of cardiovascular, renal, pulmonary and neuronal syndromes while avoiding a rebound
BR112013003823A2 (pt) 2010-08-20 2016-06-28 Cerulean Pharma Inc conjugados de peptídeo terapêutico-políemro, partículas, composições, e métodos relacionados

Also Published As

Publication number Publication date
US9358271B2 (en) 2016-06-07
PL2510942T3 (pl) 2016-02-29
WO2006110743A1 (en) 2006-10-19
US20140287999A1 (en) 2014-09-25
EP1865976A1 (en) 2007-12-19
US8710006B2 (en) 2014-04-29
PL1865976T3 (pl) 2012-11-30
US20160324931A1 (en) 2016-11-10
EP2510942A1 (en) 2012-10-17
US20110257099A1 (en) 2011-10-20
EP2510942B1 (en) 2015-09-02
EP1865976B1 (en) 2012-05-23
PT1865976E (pt) 2012-08-03
PT2510942E (pt) 2015-12-28
DK2510942T3 (en) 2015-12-14
US9023794B2 (en) 2015-05-05
ES2554713T3 (es) 2015-12-22
US20150224174A1 (en) 2015-08-13
HUE026231T2 (en) 2016-06-28
SI2510942T1 (sl) 2016-01-29
EP1865976A4 (en) 2010-09-01
ES2392892T3 (es) 2012-12-14
US7732406B2 (en) 2010-06-08
DK1865976T3 (da) 2012-07-23
US20060264376A1 (en) 2006-11-23

Similar Documents

Publication Publication Date Title
CY1113183T1 (el) Χρηση νατριουριτικου πεπτιδιου για θεραπεια καρδιακης ανεπαρκειας
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
MX2008004734A (es) Composicion rica en leucina.
EA201070121A1 (ru) Лекарственная форма, содержащая слитый белок glp-1-fc
EA201000399A1 (ru) Композиции и способы использования проостровковых пептидов и их аналогов
EA201000855A1 (ru) Способ и средства для достижения бронхиальной релаксации
EA200601776A1 (ru) Метадоновые композиции местного действия и способы их применения
NO20065232L (no) 8-(2-hydroksyfenoksy)oktyldietanolamin og salter derav for avlevering av aktive forbindelser
RS52867B (en) GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS
EP1907014A4 (en) CHONDROGENIC COMPOSITIONS AND METHODS OF USE
WO2007135182A3 (en) Factor ix analogues having prolonged in vivo half life
HRP20110969T1 (en) Pimobendan to be used for the reduction of heart size in mammals suffering from heart failure
UA116871C2 (uk) СПОСІБ ЛІКУВАННЯ МІЄЛОДИСПЛАСТИЧНОГО СИНДРОМУ, ТАЛАСЕМІЇ ТА СЕРПОПОДІБНО-КЛІТИННОЇ АНЕМІЇ ЗА ДОПОМОГОЮ ЗАСТОСУВАННЯ АНТАГОНІСТА АКТИВІНУ ПОЛІПЕПТИДУ ActRII
EA200601777A1 (ru) Новое применение пептидных соединений для лечения боли при болезненной диабетической нейропатии
BR112014007675A2 (pt) tratamento de doença articular degenerativa
SG178797A1 (en) Oligosaccharide chain added glp-1 peptide
AR113422A2 (es) Agentes tensioactivos reconstituidos que tienen propiedades mejoradas
EA200500782A1 (ru) Лечение геморрагического шока
DE602006020070D1 (de) Verringerung von schwindel, einer nebenwirkung im zusammenhang mit einer pirfenidon-therapie
BRPI0612840A8 (pt) Composição de ração para prevenir ou tratar doença renal, métodos para prevenir ou tratar doença renal e para produzir uma composição de ração, kit, e, meio para comunicar informação ou instruções
EA201000630A1 (ru) Применение бензоконденсированных гетероциклических сульфамидных производных для понижения уровней липидов в крови
DK1497330T3 (da) Antagonister af faktor-VIII-interaktion med lav-densitets- lipoproteinreceptor-relateret protein
HK1143066A1 (en) Ranolazine for elevated brain-type natriuretic peptide
EA200970127A1 (ru) Модулятор рецепторов глюкокортикостероидов и способы его применения
WO2003105774A3 (en) COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, COMPOSITIONS AND METHODS THEREOF